Drug Profile
Inarigivir soproxil/tenofovir disoproxil fumarate - F-star Therapeutics
Alternative Names: Inarigivir soproxil/tenofovir disoproxil fumarate; SB 11399; SB 9200/tenofovir disoproxil fumarate; SB 9225Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Spring Bank Pharmaceuticals
- Developer F-star Therapeutics
- Class Antiretrovirals; Antivirals; Nucleotides; Phosphonic acids; Purines; Small molecules
- Mechanism of Action DDX58 protein stimulants; NOD2 protein agonists; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
- 28 Sep 2020 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)